--- title: "[Daily Announcement] China Resources Pharmaceutical (3320) last year's net profit increased by 20% to over 4 billion, HERBS GROUP (2593) turned from profit to loss with a deficit of 23 million last year" type: "News" locale: "en" url: "https://longbridge.com/en/news/280405209.md" description: "China Resources Pharmaceutical's net profit increased by 20% to over 4 billion, with a final dividend of 12.2 cents. VIVA GOODS turned a loss into a profit, with a net profit of 170 million and a final dividend of 0.8 cents. HERBS GROUP reported a loss of 23 million and will not distribute a final dividend. UNITED LAB's net profit decreased by 21%, with a final dividend of 26 cents. Kaisa Group expects to turn a profit of over 50 billion, affected by debt restructuring. Baguio Green Group's net profit increased by 80%, with a final dividend of 7 cents" datetime: "2026-03-25T03:19:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280405209.md) - [en](https://longbridge.com/en/news/280405209.md) - [zh-HK](https://longbridge.com/zh-HK/news/280405209.md) --- # [Daily Announcement] China Resources Pharmaceutical (3320) last year's net profit increased by 20% to over 4 billion, HERBS GROUP (2593) turned from profit to loss with a deficit of 23 million last year ## China Resources Pharmaceutical's net profit increased by 20% last year, exceeding 4 billion, final dividend of 12.2 cents China Resources Pharmaceutical (3320.HK) reported a 20% year-on-year increase in net profit last year, exceeding 4 billion yuan, with a final dividend of 12.2 cents per share. Revenue during the period rose over 4% to 269.5 billion yuan. ## VIVA GOODS turned a profit of 170 million last year, final dividend of 0.8 cents VIVA GOODS (0933.HK), which holds a 14% stake in Li Ning (2331.HK), turned a profit last year with a net profit of 170 million yuan and adjusted EBITDA exceeding 1.33 billion yuan, a year-on-year increase of 46%. This was mainly due to product and pricing adjustments, improved operational efficiency, restructuring of cost structures, and optimized inventory levels and reduced holding costs. The final dividend is 0.8 cents per share. Revenue during the period fell by 1%, mainly due to a decrease in revenue from the multi-brand footwear and apparel segment, particularly from Clarks and K-Swiss. ## HERBS GROUP turned from profit to a loss of 23 million last year, no final dividend HERBS GROUP (2593.HK) reported a loss of 23 million yuan last year, turning from profit to loss. This was mainly due to a decrease in both revenue and gross profit, increased advertising and promotional expenses, and rising employee costs. Gross profit during the period was 157 million yuan, a year-on-year decrease of 13%. Revenue fell by 7% to 227 million yuan. No final dividend was declared. ## UNITED LAB's profit decreased by 21% last year, final dividend of 26 cents UNITED LAB (3933.HK) reported a 21% year-on-year decrease in profit last year, with a net profit close to 2.1 billion yuan, and a final dividend of 26 cents per share. Revenue fell nearly 4% to over 13.2 billion yuan, mainly due to a 31% and nearly 20% decline in revenue from the intermediate products and raw materials segments, respectively. ## Kaisa Group expects to turn a profit of over 50 billion last year, benefiting from debt restructuring gains Kaisa Group (1638.HK) issued a profit warning, expecting to turn a profit last year with a net profit of no less than 50 billion yuan, compared to a loss of 28.5 billion yuan in the previous year, mainly due to the recognition of gains from overseas debt restructuring. Excluding these gains, the company still recorded a loss due to a decline in revenue recognition affected by the market and increased provisions for property project impairments. ## Biyang Green's profit increased by 80% last year, final dividend of 7 cents Biyang Green Group (1397.HK) reported an 80% year-on-year increase in profit last year, with a net profit of 97.27 million yuan, and a final dividend of 7 cents per share. Revenue during the period fell nearly 7% to over 2.4 billion yuan, mainly due to declines in revenue from cleaning, waste management and recycling, and pest management, with only gardening revenue recording growth. ## WH Group's profit increased by 8% last year, final dividend of 41 Hong Kong cents WH Group (0288.HK) reported an 8% increase in profit last year. Excluding biological fair value adjustments, net profit was nearly 1.6 billion USD. After biological fair value adjustments, net profit was 1.56 billion USD, a year-on-year decrease of 2.7%. The final dividend is 41 Hong Kong cents. Revenue during the period rose by 8% to approximately 28 billion USD, mainly due to increases in pork sales and average selling prices of meat products, with meat products up 3.8%, pork up 10%, and others up 26% The group indicated that this year will continue to be filled with uncertainty, but believes that operations will remain stable. In the future, it will continue to focus on its core meat products business, implement product and channel transformations in China to respond to changes in the consumer market, and mitigate rising cost pressures in the United States to maintain high profitability levels. In Europe, it will expand its scale and enhance profit contributions. ## SenseTime's Loss Narrowed to 1.76 Billion Last Year, Generative AI Business Drives Record Revenue SenseTime (0020.HK) narrowed its loss last year to 1.76 billion yuan, compared to a loss of 4.2 billion yuan the previous year. The adjusted loss was 1.95 billion yuan, down from an adjusted loss of 4.28 billion yuan the previous year. During the period, revenue increased by nearly 33% to 5.01 billion yuan, setting a new record, mainly due to the growth of its generative artificial intelligence (AI) business ### Related Stocks - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [159929.CN](https://longbridge.com/en/quote/159929.CN.md) - [159570.CN](https://longbridge.com/en/quote/159570.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [00933.HK](https://longbridge.com/en/quote/00933.HK.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [03320.HK](https://longbridge.com/en/quote/03320.HK.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [589720.CN](https://longbridge.com/en/quote/589720.CN.md) - [03933.HK](https://longbridge.com/en/quote/03933.HK.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [520500.CN](https://longbridge.com/en/quote/520500.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [562050.CN](https://longbridge.com/en/quote/562050.CN.md) - [02593.HK](https://longbridge.com/en/quote/02593.HK.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) ## Related News & Research - [CStone’s CS2009 Posts Strong ASCO Data as Company Prepares Global Phase III Trial](https://longbridge.com/en/news/288238438.md) - [China Resources Pharmaceutical Completes RMB1.4 Billion Second Tranche of 2026 Bonds in China](https://longbridge.com/en/news/284352645.md) - [Assessing United Laboratories International Holdings (SEHK:3933) Valuation After Dupilumab Biosimilar Trial Approval](https://longbridge.com/en/news/285448082.md) - [United Laboratories Wins Green Light for Trial of Once-Weekly Insulin UBT38006](https://longbridge.com/en/news/285527106.md)